Molterfin (Buprenorphine)

Buprenorphine, the active ingredient in Molterfin, is a partial mu‑opioid receptor agonist presented as an oral formulation for oral use. It is used to manage moderate to severe pain and to support treatment of opioid dependence in appropriate patients.

GNH USA supplies Molterfin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Buprenorphine acts on the opioid receptor system to provide analgesia and aid in opioid dependence management.

- Moderate to severe pain: provides effective analgesia with a ceiling effect for respiratory depression. - Opioid dependence treatment: reduces withdrawal symptoms and cravings during detoxification. - Chronic pain management: offers long‑acting pain control for patients requiring sustained opioid therapy.

Buprenorphine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea - Constipation - Dizziness - Sedation

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Allergic reactions, including anaphylaxis

When prescribing or dispensing Molterfin, consider the following safety measures.

- Assess respiratory function: monitor patients with compromised breathing. - Evaluate hepatic function: adjust use in severe liver impairment. - Avoid abrupt discontinuation: risk of precipitated withdrawal. - Use caution in the elderly: increased sensitivity to central nervous system effects. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Buprenorphine can interact with several drug classes; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, alcohol): increased risk of respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise buprenorphine plasma levels. - Monoamine oxidase inhibitors: potential for hypertensive crisis.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic efficacy. - Other opioids: may alter overall opioid effect and increase side‑effect risk.